SCHEMBL5218192

SCHEMBL5218192

O=C(/C=C/N1CCCCC1CN1CCCC1)c1ccc(Cl)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 3/20 0.52
TP53 P04637 1/20 0.43
MAPT P10636 1/20 0.43
KDM2B Q8NHM5 2/20 0.42
OPRK1 P41145 4/20 0.41
NPC1 O15118 1/20 0.41
CYP1A2 P05177 1/20 0.41
CYP3A4 P08684 1/20 0.41
CYP2D6 P10635 1/20 0.41
CYP2C9 P11712 1/20 0.41
NFKB1 P19838 1/20 0.41
CYP2C19 P33261 1/20 0.41
OPRD1 P41143 1/20 0.41
HIF1A Q16665 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
BLM P54132 1/20 0.41
PMP22 Q01453 1/20 0.41
DRD4 P21917 1/20 0.41
SLC6A3 Q01959 1/20 0.41
TMEM97 Q5BJF2 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5221259 0.98 HRH3 (0.55) HRH3TP53MAPTKDM2BOPRK1
SCHEMBL5958398 0.96 HRH3 (0.54) HRH3TP53MAPTKDM2BOPRK1
SCHEMBL5221237 0.88 NPC1 (0.46) HRH3TP53MAPTNPC1TDP1
SCHEMBL5220645 0.85 HRH3 (0.44) HRH3SIGMAR1ALDH1A1
SCHEMBL5216163 0.85 NPC1 (0.46) HRH3TP53MAPTKDM2BNPC1
SCHEMBL5222144 0.85 NPC1 (0.46) HRH3TP53MAPTKDM2BNPC1
SCHEMBL5220594 0.85 OPRD1 (0.55) HRH3KDM2BOPRD1
SCHEMBL5223521 0.85 HRH3 (0.49) HRH3MAPTKDM2BALDH1A1
SCHEMBL5222690 0.84 HRH3 (0.44) HRH3KDM2B
SCHEMBL5223808 0.84 ALDH1A1 (0.45) HRH3TP53MAPTKDM2BNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1474419-B1 AMIDES OF AMINOALKYL-SUBSTITUTED AZETIDINES, PYRROLIDINES, PIPERIDINES AND AZEPANES NOVO NORDISK AS (DK) 2007-09-05 EP disclosed
US-7101898-B2 For therapy of allergic rhinitis, ulcer or anorexia, diabetes, Alzheimer's disease, narcolepsy or attention deficit disorder NOVO NORDISK A/S (DK) 2006-09-05 US disclosed
EP-1474419-A1 AMIDES OF AMINOALKYL-SUBSTITUTED AZETIDINES, PYRROLIDINES, PIPERIDINES AND AZEPANES NOVO NORDISK A/S (DK) 2004-11-10 EP disclosed
US-20030195190-A1 Amides of aminoalkyl-substituted azetidines, pyrrolidines, piperidines and azepanes HIGH POINT PHARMACEUTICALS, LLC 2003-10-16 US disclosed
WO-2003064411-A1 AMIDES OF AMINOALKYL-SUBSTITUTED AZETIDINES, PYRROLIDINES, PIPERIDINES AND AZEPANES NOVO NORDISK A/S (DK) 2003-08-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030195190-A1 Amides of aminoalkyl-substituted azetidines, pyrrolidines, piperidines and azepanes HRH3, HRH2, HRH4 HRH3 1/4885TP53 3111/4885MAPT 3405/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.